Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. Br Med J. 2011 Jul 4;343:d3450. doi: 10.1136/bmj.d3450
Lasry A, Sansom SL, Hicks KA, Uzunangelov V. A model for allocating CDC's HIV prevention resources in the United States. Health Care Manag Sci. 2011 Mar 1;14(1):115-24.
Earnshaw SR, Hicks K, Richter A, Honeycutt A. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci. 2007 Sep 1;10(3):239-52.
Arana JI, Jarén C, Arana A, Arazuri S. Pruebas diagnósticas en la clasificación de productos agrícolas. Horticultura. 2001;19:20-6.